



Information on the compensation of corporate officers

(in application of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code)

The combined general meeting of MaaT Pharma (the “**Company**”) which was held on June 19, 2023 at 10 a.m. at the registered office of the Company located 70 avenue Tony Garnier – 69007 Lyon, approved the resolution relating to the compensation policy for corporate officers in respect of the 2023 financial year (*Say on Pay ex-ante*), as well as the resolution relating to the information mentioned in I. of article L. 22-10-9 of the French Commercial Code (*Code de commerce*) relating to the compensation paid and/or granted to corporate officers in respect of the financial year ending December 31, 2022 (so-called “global” *Say on Pay ex-post*).

Pursuant to the provisions of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code, this information is presented below, supplemented for information purposes by the results of the votes on the resolutions relating to the individual compensation paid and/or allocated to the Company's corporate officers in respect of the financial year ending December 31, 2022 (so-called “individual” *Say on Pay ex-post*).

Resolution	Description	Results of the votes	Corresponding section in the 2022 Universal Registration Document (URD)
FOURTEENTH RESOLUTION	Approval of the information relating to the remuneration of corporate officers for the year 2022 mentioned in I of Article L. 22-10-9 of the French Commercial Code	Approved by 98,690%	Universal Registration Document (Section 13 of the URD); Paragraph 13.2 (<i>Ratio</i>)
FIFTEENTH RESOLUTION	Approval of the elements of compensation paid during or allocated by way of the financial year 2022 to the Chairman of the Board of Directors	Approved by 99,985%	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1 (<i>Corporate officers Compensation - Chairman of the Board of Directors</i>)
SIXTEENTH RESOLUTION	Approval of the elements of compensation paid during or allocated by way of the financial year 2022 to the Chief Executive Officer	Approved by 98,687%	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2 (<i>Corporate officers Compensation - CEO</i>)
SEVENTEENTH RESOLUTION	Approval of the remuneration policy applicable for 2023 to the Chairman of the Board of Directors	Approved by 98,687%	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1 (<i>Corporate officers Compensation - Chairman of the Board of Directors</i>)
EIGHTEENTH RESOLUTION	Approval of the remuneration policy applicable for 2023 to the Chief Executive Officer	Approved by 98,686%	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2 (<i>Corporate officers Compensation - CEO</i>)

NINETEENTH RESOLUTION	Approval of the remuneration policy applicable for 2023 to directors	Approved by 98,684%	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.2 (Directors compensation)
--------------------------	--	----------------------------	---

* * *

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Contacts

MaaT Pharma – Investor Relations

Hervé AFFAGARD
Co-Founder and CEO
Siân Crouzet, COO/ CFO
+33 4 28 29 14 00
invest@maat-pharma.com

MaaT Pharma – Media Relations

Pauline RICHAUD
Senior PR & Corporate Communications
Manager
+33 6 14 06 45 92
media@maat-pharma.com

Trophic Communications – Corporate Communications

Stephanie MAY or
Charlotte SPITZ
+49 171 351 2733
maat@trophic.eu